Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives $29.15 Consensus PT from Analysts

Capricor Therapeutics, Inc. (NASDAQ:CAPR) has been assigned a consensus rating of “Hold” from the eleven analysts that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, nine have assigned a hold recommendation and one has given a buy recommendation to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $29.15.

A number of equities research analysts have commented on CAPR shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Capricor Therapeutics in a research note on Monday, June 15th. B. Riley Financial cut shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $10.00 target price for the company. in a research note on Monday, July 27th. HC Wainwright reissued a “neutral” rating on shares of Capricor Therapeutics in a research report on Monday, July 27th. Cantor Fitzgerald raised shares of Capricor Therapeutics from a “neutral” rating to an “overweight” rating in a report on Friday, August 14th. Finally, Wall Street Zen downgraded shares of Capricor Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 1st.

Capricor Therapeutics News Summary

Here are the key news stories impacting Capricor Therapeutics this week:

• Positive Sentiment: The FDA extended the PDUFA target action date for deramiocel by three months to November 22, 2026. Capricor said the extension follows submission of additional Phase 3 HOPE-3 data and analyses supporting a refined proposed indication, keeping a potential approval decision alive. Capricor FDA review extension
• Neutral Sentiment: Analysts and investors are reassessing the regulatory timeline following reports that FDA briefing materials raised questions about changes to the HOPE-3 statistical analysis plan. The continued review preserves upside potential, but the delay increases uncertainty around approval and commercialization timing. Reuters FDA review report
• Negative Sentiment: Multiple law firms publicized a securities-fraud class action covering investors who purchased CAPR between December 17, 2025, and July 26, 2026. The allegations include material misstatements or omissions regarding deramiocel’s statistical analysis plan, FDA compliance, and the path to approval. Investors have generally been given until September 28, 2026 to seek lead-plaintiff status. These announcements add legal overhang and may further damage investor confidence, although the allegations have not been proven. Capricor securities class action
• Negative Sentiment: Recent coverage also highlighted weak quarterly results, including an earnings-per-share loss that missed analyst expectations, and the absence of a management question-and-answer session during the earnings call. CAPR has experienced a steep decline from its 12-month high, with unusually heavy trading volume underscoring elevated risk.

Insider Buying and Selling

In related news, CFO Anthony Bergmann sold 24,100 shares of Capricor Therapeutics stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $30.38, for a total transaction of $732,158.00. Following the completion of the sale, the chief financial officer owned 11,223 shares of the company’s stock, valued at $340,954.74. The trade was a 68.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last ninety days, insiders sold 25,000 shares of company stock worth $759,158. Insiders own 9.20% of the company’s stock.

Institutional Trading of Capricor Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Suvretta Capital Management LLC purchased a new position in shares of Capricor Therapeutics during the 4th quarter valued at about $51,533,000. Tang Capital Management LLC purchased a new stake in shares of Capricor Therapeutics in the fourth quarter worth about $49,062,000. RA Capital Management L.P. purchased a new stake in Capricor Therapeutics in the 4th quarter worth approximately $43,516,000. California State Teachers Retirement System grew its stake in shares of Capricor Therapeutics by 2,261.8% during the 2nd quarter. California State Teachers Retirement System now owns 1,528,478 shares of the biotechnology company’s stock worth $36,806,000 after purchasing an additional 1,463,762 shares during the period. Finally, Darwin Global Management Ltd. acquired a new stake in shares of Capricor Therapeutics during the 4th quarter worth approximately $23,168,000. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics Trading Up 8.1%

Shares of NASDAQ:CAPR opened at $6.80 on Tuesday. Capricor Therapeutics has a 12-month low of $2.96 and a 12-month high of $40.37. The business’s fifty day simple moving average is $15.93 and its 200-day simple moving average is $24.72. The company has a market capitalization of $395.35 million, a PE ratio of -2.78 and a beta of 0.54.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings data on Thursday, August 13th. The biotechnology company reported ($0.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.11). Research analysts predict that Capricor Therapeutics will post -1.65 EPS for the current year.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.